Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Gene Replacement Therapy
1.2.3 Gene Silencing Therapy
1.2.4 Gene Editing Therapy
1.2.5 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospitals and Clinics
1.3.3 Research Institutions
1.3.4 Biotechnology Companies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Perspective (2018-2033)
2.2 Global Gene Therapy for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2033)
2.3 Gene Therapy for Neurodegenerative Diseases Market Dynamics
2.3.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
2.3.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
2.3.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
2.3.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Gene Therapy for Neurodegenerative Diseases by Players
3.1.1 Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
3.5 Global Key Players of Gene Therapy for Neurodegenerative Diseases Head office and Area Served
3.6 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
3.7 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033)
5 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
6.2 North America Gene Therapy for Neurodegenerative Diseases Market Size by Type
6.2.1 North America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
6.2.2 North America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
6.2.3 North America Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Application
6.3.1 North America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.3.2 North America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
6.3.3 North America Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
6.4 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country
6.4.1 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
6.4.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type
7.2.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
7.2.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
7.2.3 Europe Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application
7.3.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
7.3.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
7.3.3 Europe Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
7.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country
7.4.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
7.4.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
8.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Type
8.2.1 China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
8.2.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
8.2.3 China Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
8.3 China Gene Therapy for Neurodegenerative Diseases Market Size by Application
8.3.1 China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
8.3.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
8.3.3 China Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
9.2 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Type
9.2.1 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
9.2.2 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
9.2.3 Asia Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
9.3 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Application
9.3.1 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
9.3.2 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
9.3.3 Asia Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
9.4 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region
9.4.1 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023)
9.4.3 Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Type
10.2.1 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Application
10.3.1 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country
10.4.1 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Details
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.1.5 Voyager Therapeutics Recent Developments
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Details
11.2.2 Uniqure N.V. Business Overview
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
11.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.2.5 Uniqure N.V. Recent Developments
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Details
11.3.2 Axovant Gene Therapies Business Overview
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
11.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.3.5 Axovant Gene Therapies Recent Developments
11.4 Novartis Ag
11.4.1 Novartis Ag Company Details
11.4.2 Novartis Ag Business Overview
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
11.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.4.5 Novartis Ag Recent Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Details
11.5.2 Amicus Therapeutics Business Overview
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.5.5 Amicus Therapeutics Recent Developments
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Details
11.6.2 Regenxbio Inc. Business Overview
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
11.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.6.5 Regenxbio Inc. Recent Developments
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Details
11.7.2 Sarepta Therapeutics Business Overview
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.7.5 Sarepta Therapeutics Recent Developments
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Details
11.8.2 Gensight Biologics Business Overview
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
11.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.8.5 Gensight Biologics Recent Developments
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Details
11.9.2 Krystal Biotech Business Overview
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
11.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.9.5 Krystal Biotech Recent Developments
11.10 Avexis
11.10.1 Avexis Company Details
11.10.2 Avexis Business Overview
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
11.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
11.10.5 Avexis Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Gene Replacement Therapy
Table 3. Key Players of Gene Silencing Therapy
Table 4. Key Players of Gene Editing Therapy
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2023)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2024-2033)
Table 12. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 14. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 15. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 16. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Players (2018-2023)
Table 18. Global Top Gene Therapy for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Table 19. Global Gene Therapy for Neurodegenerative Diseases Industry Ranking 2021 VS 2022 VS 2023
Table 20. Global 5 Largest Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue (CR5 and HHI) & (2018-2023)
Table 21. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Headquarters and Area Served
Table 22. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
Table 23. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2023)
Table 27. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2024-2033)
Table 29. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Application (2018-2023)
Table 31. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Application (2024-2033)
Table 33. North America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 34. North America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 35. North America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 36. North America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 37. North America Gene Therapy for Neurodegenerative Diseases Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 40. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 42. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 43. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 44. Europe Gene Therapy for Neurodegenerative Diseases Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 46. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 47. China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 48. China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 49. China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 50. China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 51. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 52. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 53. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 54. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 55. Asia Gene Therapy for Neurodegenerative Diseases Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 56. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 57. Asia Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 63. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 65. Voyager Therapeutics Company Details
Table 66. Voyager Therapeutics Business Overview
Table 67. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 68. Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 69. Voyager Therapeutics Recent Developments
Table 70. Uniqure N.V. Company Details
Table 71. Uniqure N.V. Business Overview
Table 72. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product
Table 73. Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 74. Uniqure N.V. Recent Developments
Table 75. Axovant Gene Therapies Company Details
Table 76. Axovant Gene Therapies Business Overview
Table 77. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product
Table 78. Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 79. Axovant Gene Therapies Recent Developments
Table 80. Novartis Ag Company Details
Table 81. Novartis Ag Business Overview
Table 82. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product
Table 83. Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 84. Novartis Ag Recent Developments
Table 85. Amicus Therapeutics Company Details
Table 86. Amicus Therapeutics Business Overview
Table 87. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 88. Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 89. Amicus Therapeutics Recent Developments
Table 90. Regenxbio Inc. Company Details
Table 91. Regenxbio Inc. Business Overview
Table 92. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product
Table 93. Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 94. Regenxbio Inc. Recent Developments
Table 95. Sarepta Therapeutics Company Details
Table 96. Sarepta Therapeutics Business Overview
Table 97. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 98. Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 99. Sarepta Therapeutics Recent Developments
Table 100. Gensight Biologics Company Details
Table 101. Gensight Biologics Business Overview
Table 102. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product
Table 103. Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 104. Gensight Biologics Recent Developments
Table 105. Krystal Biotech Company Details
Table 106. Krystal Biotech Business Overview
Table 107. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product
Table 108. Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 109. Krystal Biotech Recent Developments
Table 110. Avexis Company Details
Table 111. Avexis Business Overview
Table 112. Avexis Gene Therapy for Neurodegenerative Diseases Product
Table 113. Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 114. Avexis Recent Developments
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type: 2022 VS 2033
Figure 3. Gene Replacement Therapy Features
Figure 4. Gene Silencing Therapy Features
Figure 5. Gene Editing Therapy Features
Figure 6. Enzyme Replacement Therapy Features
Figure 7. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application: 2022 VS 2033
Figure 9. Hospitals and Clinics Case Studies
Figure 10. Research Institutions Case Studies
Figure 11. Biotechnology Companies Case Studies
Figure 12. Others Case Studies
Figure 13. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 14. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region: 2022 VS 2033
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players in 2022
Figure 18. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
Figure 20. North America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 22. North America Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 23. North America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 24. United States Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Gene Therapy for Neurodegenerative Diseases Market Size YoY (2018-2033) & (US$ Million)
Figure 27. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 28. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 29. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 30. Germany Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. China Gene Therapy for Neurodegenerative Diseases Market Size YoY (2018-2033) & (US$ Million)
Figure 37. China Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 38. China Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 39. Asia Gene Therapy for Neurodegenerative Diseases Market Size YoY (2018-2033) & (US$ Million)
Figure 40. Asia Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 41. Asia Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 42. Asia Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2033)
Figure 43. Japan Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. South Korea Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. China Taiwan Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. India Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Australia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Size YoY (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 51. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 52. Middle East, Africa, and Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 53. Brazil Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Mexico Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Turkey Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Israel Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. Voyager Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 60. Uniqure N.V. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 61. Axovant Gene Therapies Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 62. Novartis Ag Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 63. Amicus Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 64. Regenxbio Inc. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 65. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 66. Gensight Biologics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 67. Krystal Biotech Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 68. Avexis Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed